Gossamer Bio's (GOSS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Gossamer Bio (NASDAQ:GOSS - Free Report) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Gossamer Bio's Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS, FY2027 earnings at ($0.04) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.55 EPS.

Separately, Wedbush reaffirmed an "outperform" rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $9.20.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS traded up $0.04 during trading hours on Tuesday, hitting $1.39. 1,068,430 shares of the company's stock traded hands, compared to its average volume of 1,564,338. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The company's fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $0.98. The company has a market cap of $315.84 million, a price-to-earnings ratio of -4.34 and a beta of 1.86.

Remove Ads

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts' consensus estimates of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analysts' expectations of $7.02 million. As a group, equities analysts anticipate that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Trading of Gossamer Bio

A number of hedge funds have recently made changes to their positions in the stock. Octagon Capital Advisors LP lifted its position in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock worth $16,599,000 after purchasing an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock worth $7,968,000 after purchasing an additional 3,041,058 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock worth $5,583,000 after purchasing an additional 526,495 shares in the last quarter. Monaco Asset Management SAM lifted its position in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Gossamer Bio by 14.6% in the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company's stock worth $3,244,000 after purchasing an additional 457,179 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.